Research & writings
Notes from a two-act career.
Currently in act two — biotech, antisense oligonucleotides, rare disease drug development. Act one was machine consciousness research. Both sections live below.
Therapeutics
Current focus. CYFIP1 ASO program at Longinus Therapeutics — rare-disease drug development, regulatory economics, and the engineering of antisense oligonucleotides for 15q11.2 BP1-BP2 microduplication.
- Jun 16, 2026 Turning a Gene Down Without Editing It
- Jun 8, 2026 The Priority Review Voucher Math
- Jun 7, 2026 The Idiot Index Applied to Rare Disease Drug Development
- Jun 5, 2026 iPSC Neurons as a Patient-of-One Validation Model
- Jun 3, 2026 Why ATTUNE Matters More Than People Think
- May 31, 2026 The U-Shape of CYFIP1 Dosage
- May 29, 2026 From Machine Cognition to Programmable Medicine
- May 25, 2026 ASO Design as Software Engineering
- May 20, 2026 CYFIP1 and the Open Niche in 15q11.2
Genetics
The dosage-sensitive biology of the human brain — gene dosage, neurodevelopment, and what modern genetics says about the old link between brilliance and madness.
Machine Consciousness
Earlier work. Integrated information theory, global workspace theory, transformer interpretability, and the question of what it would take for a machine to have an inside.
- Mar 22, 2026 Opening the Black Box: Building a Conscious Agent on Open-Weights Models
- Mar 15, 2026 Fractal Partitioning Theory: Consciousness as Boundary Friction
- Mar 15, 2026 The Speed of a Thought: Why Consciousness Has a Size Limit — and What That Means for AI, Ants, and the Internet
- Jan 20, 2025 Global Workspace Theory and Artificial Minds
- Jan 18, 2025 The Hard Problem for Machines
- Jan 15, 2025 Challenges in Superposition: Representational Geometry and Machine Consciousness
- Jan 12, 2025 Measuring Φ: Practical Challenges for IIT
- Jan 8, 2025 Qualia and Silicon: Could Machines Have Phenomenal Experience?
- Jan 5, 2025 LLM Architecture and the Integrated Information Framework